Skip to content

Study · Animal study (in vivo) · rat · 2010

6 results

Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system.

Pérez-Tilve D, González-Matías L, Aulinger BA, Alvarez-Crespo M, Gil-Lozano M, Alvarez E, Andrade-Olivie AM, Tschöp MH, D'Alessio DA, Mallo F, Mallo F

American journal of physiology. Endocrinology and metabolism2 Mar 2010Cited by 51 (Europe PMC)

PMID20197503 (opens in a new tab)PMCIDPMC2867369 (opens in a new tab)DOI10.1152/ajpendo.00464.2009 (opens in a new tab)PepBankPUB-20197503
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats, acute high-dose exendin‑4 increased blood glucose after peripheral or central administration.

    In plain wordsIn rats, high doses of exendin‑4 acutely increased blood glucose after peripheral or brain administration.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAcute blood glucose
    Study

    ratn: not reported in source

    rats
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · peripheral circulation or CNSAs given in this study (rat).

    Source sentences

    Summary
    Here, we report that acute administration of Ex-4, in relatively high doses, into either the peripheral circulation or the CNS, paradoxically increased blood glucose levels in rats.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats, the potency of exendin‑4 to increase blood glucose waned with chronic administration.

    In plain wordsIn rats, exendin‑4 became less potent at increasing blood glucose with repeated administration.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseChronic hyperglycemic potency
    Study

    ratn: not reported in source

    rats
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 daysAs given in this study (rat).

    Source sentences

    Summary
    The potency of Ex-4 to elevate blood glucose waned with chronic administration such that after 6 days the familiar actions of Ex-4 to improve glucose tolerance were evident.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, exendin‑4 improved glucose tolerance after chronic administration.

    In plain wordsIn rats, exendin‑4 improved glucose tolerance after repeated administration.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseGlucose tolerance
    Study

    ratn: not reported in source

    rats
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 daysAs given in this study (rat).

    Source sentences

    Summary
    The potency of Ex-4 to elevate blood glucose waned with chronic administration such that after 6 days the familiar actions of Ex-4 to improve glucose tolerance were evident.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats, acute exendin‑4-induced hyperglycemia was independent of its insulinotropic and HPA-activating actions.

    In plain wordsIn rats, the blood glucose increase from exendin‑4 was independent of its insulin-releasing and stress hormone actions.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableIndependence of acute hyperglycemia from insulinotropic and HPA actions
    Study

    ratn: not reported in source

    rats
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated · peripheral circulation or CNSAs given in this study (rat).

    Source sentences

    Summary
    This effect was independent of the insulinotropic and hypothalamic-pituitary-adrenal activating actions of Ex-4 and could be blocked by a GLP-1R antagonist.
    1 context sentence
    Summary · context
    Here, we report that acute administration of Ex-4, in relatively high doses, into either the peripheral circulation or the CNS, paradoxically increased blood glucose levels in rats.

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 05AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Mechanism

    In rats, a GLP-1 receptor antagonist blocked exendin‑4-induced hyperglycemia.

    In plain wordsIn rats, a GLP-1 receptor blocker prevented the blood glucose increase induced by exendin‑4.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGLP-1 receptor dependence of hyperglycemia
    Study

    ratn: not reported in source

    rats
    Outcome group
    Receptor activity and mechanism · Metabolic and weight

    Source sentences

    Summary
    This effect was independent of the insulinotropic and hypothalamic-pituitary-adrenal activating actions of Ex-4 and could be blocked by a GLP-1R antagonist.
    1 context sentence
    Summary · context
    Here, we report that acute administration of Ex-4, in relatively high doses, into either the peripheral circulation or the CNS, paradoxically increased blood glucose levels in rats.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 06AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Mechanism

    In rats, hexamethonium, guanethidine, and adrenal medullectomy blocked exendin‑4-induced hyperglycemia, indicating sympathetic mediation.

    In plain wordsIn rats, nerve-blocking treatments or adrenal medullectomy blocked the blood glucose increase induced by exendin‑4.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSympathetic dependence of hyperglycemia
    Study

    ratn: not reported in source

    rats
    Outcome group
    Receptor activity and mechanism · Metabolic and weight

    Source sentences

    Summary
    Acute hyperglycemia induced by Ex-4 was blocked by hexamethonium, guanethidine, and adrenal medullectomy, indicating that this effect was mediated by sympathetic nervous system (SNS) activation.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.